Paper Details

  1. Home
  2. Paper Details

Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial.

Author: BaoYan, CongLi, DengChunying, DengXiangqun, DongQijuan, DuanPeng, HuangChenghu, HuangQingmei, JiangChengxia, LiHongMei, LiMeizi, LiShu, LiXuefeng, LiZiling, LiuJianying, MaJianhua, MaYujin, NiLin, PanTianrong, PangShuguang, PengHui, PengWeixia, PiYinzhen, QinLi, ShenXingping, SongWeihong, SuXiuhai, SunJingchao, SunKan, SunLi, SunQingyuan, WangChuan, WangFujun, WangGuang, WangHaifang, WangJianping, WangKun, WangYanjun, WuChaoming, WuXiaohong, XiJue, XiaoRijun, XieZuoling, XuMingtong, XuNing, XuWenjie, YanDewen, YanLi, YanShuang, ZengTianshu, ZhangLi, ZhangMeiying, ZhangWei, ZhangXin, ZhangYawei, ZhengXianling, ZouQijing

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This clinical trial assessed the efficacy and safety of fotagliptin, a novel DPP-4 inhibitor, in treatment-naive patients with type 2 diabetes mellitus.
Paper Details　
Original Abstract of the Article :
Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become firmly established in treatment algorithms and national guidelines for improving glycemic control in type 2 diabetes mellitus (T2DM).To report the findings from a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563289/

データ提供：米国国立医学図書館（NLM）

Fotagliptin Monotherapy in Patients with Uncontrolled Type 2 Diabetes Mellitus

Diabetes, a condition characterized by high blood sugar levels, is a growing concern worldwide. This research focuses on a new drug called fotagliptin, which belongs to a class of medications called dipeptidyl peptidase-4 inhibitors (DPP-4i). These drugs work by enhancing the body's natural ability to regulate blood sugar levels. The study aimed to assess the effectiveness and safety of fotagliptin in patients with type 2 diabetes who were not adequately controlled with other treatments.

Fotagliptin's Potential as a Treatment Option

This clinical trial found that fotagliptin effectively improved blood sugar control in patients with type 2 diabetes. The results demonstrate fotagliptin's potential as a valuable addition to the treatment arsenal for diabetes management.

Fotagliptin's Impact on Diabetes Management

This study offers hope to individuals struggling with uncontrolled type 2 diabetes. Fotagliptin, along with other lifestyle modifications and existing diabetes treatments, may provide a pathway toward better blood sugar control. It's crucial to consult with a healthcare professional to determine the best treatment plan for your individual needs.

Dr.Camel's Conclusion

Fotagliptin is like a camel navigating a desert, seeking out the best routes to keep blood sugar levels balanced. It's a promising addition to the diabetes management toolkit, but it's important to remember that each individual's journey with diabetes is unique, and the best approach may vary.

Date :
  1. Date Completed 2023-11-01
  2. Date Revised 2023-11-20
Further Info :

Pubmed ID

37814306

DOI: Digital Object Identifier

PMC10563289

Related Literature

Article Analysis
・Effects of alogliptin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.